FDA OKs Second-Line Drug Therapy For CAP
The US Food and Drug Administration (FDA) has approved a supplemental new drug application for Avelox® (moxifloxacin HCl) for the treatment of community-acquired pneumonia (CAP) caused by multidrug-resistant Streptococcus pneumoniae. Manufacturer Bayer Pharmaceuticals Corp of West Haven, Conn, says Avelox is the first antibiotic available in both tablet and IV forms approved to treat CAP caused by these strains, which the company says are resistant to the antibiotics most commonly used to treat pneumonia. Bayer reports that Avelox demonstrated excellent clinical and bacteriological success against strains resistant to two to five commonly used antibiotics, including macrolides such as clarithromycin and azithromycin, penicillin, second-generation cepholosporins such as cefuroxime, trimethoprim-sulfamethoxazole, and tetracyclines with eradication rates of 93% to 100%.

Carefore Medical Changes Ownership
In May, CareFore Medical Inc transacted a change in ownership. Sean C. Squire, who founded the Lenexa, Kan-based company with Pamela Squire in 1996, acquired 100% of the company’s stock. Squire’s former business partner and the corporation’s only other stockholder, L. Robert Mogue, the former executive vice president, sales and marketing, is now consulting with the company in sales, marketing, and quality systems. Carefore develops, manufactures, and distributes respiratory accessories to the home health care and hospital market worldwide.